Table 1.
Compound | HeLa | K562 | MCF7 | HUVEC |
---|---|---|---|---|
1 | 11.0 ± 6.4 | 4.2 ± 1.3 | 3 ± 1.4 | 3 ± 2.9 |
2 | >100 | 62 ± 6.9 | 18 ± 1.4 | 30 ± 4.0 |
3 | >100 | 88 ± 9.2 | 28 ± 1.3 | 160 ± 6.9 |
4 | 55 ± 5.8 1 | 20 ± 1.2 2 | 18 ± 2.1 1 | 9 ± 1.0 |
5 | 20 ± 1.9 1 | 30 ± 1.5 2 | 15 ± 4.9 1 | 30 ± 2.8 |
8 | >100 | 18 ± 3.6 | 20 ± 1.0 | 21 ± 3.1 |
9 | >100 | 85 ± 8.4 | 20 ± 1.8 | 31 ± 6.0 |
10 | 21 ± 5.6 | 22 ± 7.8 | 18 ± 0.9 | 20 ± 2.8 |
11 | 20 ± 4.0 | 32 ± 5.7 | 10 ± 0.9 | 20 ± 2.7 |
Cis-Pt | Nd 3 | >50 | Nd 3 | 15 ± 1.54 |
Doxorubicin | 0.5 ± 0.01 | 1.1 ± 0.06 | Nd 3 | 0.4 ± 0.14 |
1 During MTT assay, medium was replaced before addition of tetrazolium salt; 2 Determined by ATP measurement using CellTiter-Glo luminescence cell viability assay; 3 Not determined.